AU2014324080B2 - Autoantibody biomarkers of ovarian cancer - Google Patents

Autoantibody biomarkers of ovarian cancer Download PDF

Info

Publication number
AU2014324080B2
AU2014324080B2 AU2014324080A AU2014324080A AU2014324080B2 AU 2014324080 B2 AU2014324080 B2 AU 2014324080B2 AU 2014324080 A AU2014324080 A AU 2014324080A AU 2014324080 A AU2014324080 A AU 2014324080A AU 2014324080 B2 AU2014324080 B2 AU 2014324080B2
Authority
AU
Australia
Prior art keywords
autoantibody
ovarian cancer
subject
autoantibodies
associated autoantibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014324080A
Other languages
English (en)
Other versions
AU2014324080A1 (en
Inventor
Peter Hoffmann
Karina MARTIN
Martin Oehler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innovation and Commercial Partners Pty Ltd
Original Assignee
Adelaide Research and Innovation Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2013903595A external-priority patent/AU2013903595A0/en
Application filed by Adelaide Research and Innovation Pty Ltd filed Critical Adelaide Research and Innovation Pty Ltd
Priority to AU2014324080A priority Critical patent/AU2014324080B2/en
Publication of AU2014324080A1 publication Critical patent/AU2014324080A1/en
Application granted granted Critical
Publication of AU2014324080B2 publication Critical patent/AU2014324080B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Rehabilitation Therapy (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2014324080A 2013-09-18 2014-09-18 Autoantibody biomarkers of ovarian cancer Active AU2014324080B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2014324080A AU2014324080B2 (en) 2013-09-18 2014-09-18 Autoantibody biomarkers of ovarian cancer

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AU2013903595 2013-09-18
AU2013903595A AU2013903595A0 (en) 2013-09-18 Autoantibody biomarkers of ovarian cancer
PCT/AU2014/000925 WO2015039175A1 (en) 2013-09-18 2014-09-18 Autoantibody biomarkers of ovarian cancer
AU2014324080A AU2014324080B2 (en) 2013-09-18 2014-09-18 Autoantibody biomarkers of ovarian cancer

Publications (2)

Publication Number Publication Date
AU2014324080A1 AU2014324080A1 (en) 2016-04-14
AU2014324080B2 true AU2014324080B2 (en) 2020-07-23

Family

ID=52687999

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014324080A Active AU2014324080B2 (en) 2013-09-18 2014-09-18 Autoantibody biomarkers of ovarian cancer

Country Status (7)

Country Link
US (3) US20160291025A1 (enExample)
EP (1) EP3047277B1 (enExample)
JP (1) JP6588893B2 (enExample)
CN (1) CN105745543B (enExample)
AU (1) AU2014324080B2 (enExample)
CA (1) CA2924600A1 (enExample)
WO (1) WO2015039175A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107056888A (zh) * 2017-03-01 2017-08-18 中山大学肿瘤防治中心 Atp1a1靶向多肽及应用
CN109116024B (zh) * 2018-06-14 2021-04-23 郑州大学第一附属医院 一种肺癌标志物抗-actr3自身抗体及其应用
GB201813137D0 (en) 2018-08-10 2018-09-26 Medannex Ltd Cancer treatment with an antibody
CN109182260A (zh) * 2018-09-11 2019-01-11 邵勇 一种体外培养胎膜间充质干细胞的方法
CN109480771B (zh) * 2018-10-17 2021-09-07 江西惠肽生物科技有限公司 一种卵巢肿块良恶的确定方法及确定装置
CN113785199B (zh) * 2019-03-01 2024-02-09 先进标志物探索公司 用于诊断结肠直肠癌和/或其癌前阶段的蛋白质特征
AU2020368546A1 (en) * 2019-10-16 2022-05-26 Icahn School Of Medicine At Mount Sinai Systems and methods for detecting a disease condition
US12152280B2 (en) 2021-09-20 2024-11-26 Droplet Biosciences, Inc. Drain fluid for diagnostics

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020168696A1 (en) * 1999-08-06 2002-11-14 Samir M. Hanash Annexin proteins and autoantibodies as serum markers for cancer
WO2010070043A1 (en) * 2008-12-19 2010-06-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Biomarkers for the diagnosis of renal allograft and kidney status

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1161262B1 (en) * 1999-03-15 2008-05-21 University of Maryland, Baltimore SURFACE LOCALIZED COLLIGIN/HsP47 IN CARCINOMA CELLS
US20020037286A1 (en) * 2000-04-03 2002-03-28 Matthias Krause Methods for altering T cell and macrophage activation
US8614169B2 (en) * 2001-12-04 2013-12-24 Wayne State University Neoepitope detection of disease using protein arrays
EP1540010B8 (en) * 2002-08-06 2010-07-14 The Johns Hopkins University Use of biomarkers for detecting ovarian cancer
CN101268367A (zh) * 2005-06-24 2008-09-17 赛弗吉生物系统公司 卵巢癌的生物标记
AU2007211085A1 (en) * 2006-01-27 2007-08-09 Tripath Imaging, Inc. Methods for identifying patients with an increased likelihood of having ovarian cancer and compositions therefor
AU2007297310B2 (en) 2006-09-13 2013-11-07 Oncimmune Limited Improved immunoassay methods
WO2008115710A2 (en) * 2007-03-07 2008-09-25 The Johns Hopkins University Biomarkers for cancer
JP5265140B2 (ja) * 2007-06-14 2013-08-14 学校法人日本医科大学 卵巣癌の検出方法及び検出用キット
EP2637020A3 (en) * 2007-06-29 2014-01-08 Correlogic Systems Inc. Predictive markers for ovarian cancer
RU2571687C2 (ru) * 2007-11-13 2015-12-20 Феникс Байотекнолоджи Инк. Набор для определения вероятности терапевтического ответа на противораковую химиотерапию сердечным гликозидом
EP2277049A4 (en) * 2008-05-09 2012-05-30 Univ Duke AUTOANTIKÖRPER FOR THE PROOF AND THE TREATMENT OF CANCER
US20120004289A1 (en) * 2009-03-06 2012-01-05 The Johns Hopkins University Annexin a11 and associated genes as biomarkers for cancer
CN101762699A (zh) * 2009-06-24 2010-06-30 北京科美东雅生物技术有限公司 一种定量检测血液中肿瘤相关抗原125的磁性免疫层析试纸条及制备方法
US20120277326A1 (en) 2009-11-20 2012-11-01 Taylor Douglas D Biomarkers of cancer
JP2011257147A (ja) * 2010-06-04 2011-12-22 Nitto Boseki Co Ltd データ収集方法、キット及び腫瘍マーカー
WO2013112801A1 (en) * 2012-01-26 2013-08-01 Ibc Pharmaceuticals, Inc. Targeting interferon-lambda with antibodies potently enhances anti-tumor and anti-viral activities
CN102590531A (zh) * 2012-03-24 2012-07-18 广西壮族自治区肿瘤防治研究所 卵巢癌相关抗原自身抗体谱液相芯片检测试剂盒及其制备方法
JP5574348B2 (ja) * 2012-05-31 2014-08-20 国立大学法人 千葉大学 肺サルコイドーシスおよび眼サルコイドーシスの検出マーカー及び検出キット
US20140179808A1 (en) * 2012-10-23 2014-06-26 Bio-Rad Laboratories, Inc. Detection of Ovarian Carcinoma by Assay for Autoantibodies to Multiple Antigens
EP2951592A4 (en) 2013-01-31 2017-01-04 Arizona Board of Regents, a Body Corporate of the State of Arizona acting for and on behalf of Arizona State University Autoantibody signature for the early detection of ovarian cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020168696A1 (en) * 1999-08-06 2002-11-14 Samir M. Hanash Annexin proteins and autoantibodies as serum markers for cancer
WO2010070043A1 (en) * 2008-12-19 2010-06-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Biomarkers for the diagnosis of renal allograft and kidney status

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MARTIN, K. et al., International Journal of Molecular Sciences, 2011 Vol. 12, No. 1, pages 410-428 *

Also Published As

Publication number Publication date
US20220365088A1 (en) 2022-11-17
WO2015039175A1 (en) 2015-03-26
US12287337B2 (en) 2025-04-29
CN105745543A (zh) 2016-07-06
US20160291025A1 (en) 2016-10-06
JP2016536568A (ja) 2016-11-24
EP3047277A1 (en) 2016-07-27
US20190219584A1 (en) 2019-07-18
EP3047277A4 (en) 2017-05-10
CA2924600A1 (en) 2015-03-26
JP6588893B2 (ja) 2019-10-09
AU2014324080A1 (en) 2016-04-14
CN105745543B (zh) 2018-02-02
EP3047277B1 (en) 2018-11-21
US11371993B2 (en) 2022-06-28

Similar Documents

Publication Publication Date Title
US12287337B2 (en) Autoantibody biomarkers of ovarian cancer
US11525003B2 (en) Anti-B7-H3 antibodies and diagnostic uses thereof
JP6666905B2 (ja) Ｐｄ−ｌ１抗体及びその使用
EP3283886B1 (en) Methods for treating lung cancer
US20190202930A1 (en) Methods for treatment of ovarian cancer
US8420091B2 (en) Matriptase protein and uses thereof
AU2023210591A1 (en) Markers of endometrial cancer
US9206258B2 (en) Anti-prostate cancer antibodies and methods of detection and treatment of prostate cancer using the same
US20200309780A1 (en) Plasma biomarker for ovarian cancer
CN114902048A (zh) 伴随诊断用生物标志物组合物及包含其的伴随诊断用试剂盒
WO2019064073A1 (en) USE OF CA125 FOR PREDICTING ANTI-MESOTHELIC TREATMENT OF MESOTHELIOMES

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)